Advanced Proteome Therapeutics Corporation
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and i… Read more
Advanced Proteome Therapeutics Corporation (APTCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of April 2023: 32.745x
Based on the latest financial reports, Advanced Proteome Therapeutics Corporation (APTCF) has a cash flow conversion efficiency ratio of 32.745x as of April 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-711.78K) by net assets ($-21.74K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Advanced Proteome Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (1997–2022)
This chart illustrates how Advanced Proteome Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Advanced Proteome Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Advanced Proteome Therapeutics Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACL Cables PLC
CM:ACLN0000
|
N/A |
|
Northern Star Investment Corp III
PINK:NSTC
|
-0.009x |
|
SKYWORTH DIGITAL (KYW.SG)
STU:KYW
|
N/A |
|
WHRL4F
SA:WHRL4F
|
N/A |
|
Likewise Group PLC
LSE:LIKE
|
0.122x |
|
Afastor Corporation
TWO:6707
|
-0.013x |
|
SKYWORTH DIGITAL
MU:KYW
|
N/A |
|
Dyna Group International Inc
PINK:DGIX
|
N/A |
Annual Cash Flow Conversion Efficiency for Advanced Proteome Therapeutics Corporation (1997–2022)
The table below shows the annual cash flow conversion efficiency of Advanced Proteome Therapeutics Corporation from 1997 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-07-31 | $-850.89K | $-693.58K | 0.815x | +207.86% |
| 2021-07-31 | $-2.06 Million | $-545.20K | 0.265x | -21.64% |
| 2020-07-31 | $-1.38 Million | $-466.98K | 0.338x | -54.94% |
| 2019-07-31 | $-914.41K | $-685.70K | 0.750x | -44.55% |
| 2018-07-31 | $-896.36K | $-1.21 Million | 1.352x | +45.67% |
| 2017-07-31 | $-789.29K | $-732.84K | 0.928x | -43.76% |
| 2016-07-31 | $-487.17K | $-804.31K | 1.651x | +132.87% |
| 2015-07-31 | $200.40K | $-1.01 Million | -5.022x | -330.82% |
| 2014-07-31 | $-405.97K | $-883.34K | 2.176x | +103.84% |
| 2013-07-31 | $-723.68K | $-772.49K | 1.067x | -27.97% |
| 2012-07-31 | $-367.02K | $-543.93K | 1.482x | +121.39% |
| 2011-07-31 | $129.06K | $-894.26K | -6.929x | -162.67% |
| 2010-07-31 | $341.78K | $-901.63K | -2.638x | -290.06% |
| 2009-07-31 | $1.34 Million | $-905.30K | -0.676x | -49.12% |
| 2008-07-31 | $2.41 Million | $-1.09 Million | -0.454x | +14.55% |
| 2007-07-31 | $1.44 Million | $-765.40K | -0.531x | -153.03% |
| 2006-07-31 | $-1.17K | $-1.17K | 1.001x | +70.07% |
| 2005-07-31 | $58.94K | $34.69K | 0.588x | +861.50% |
| 2004-07-31 | $-2.57 Million | $198.56K | -0.077x | -274.12% |
| 2003-07-31 | $-2.50 Million | $-111.14K | 0.044x | +37.73% |
| 2002-07-31 | $-8.23 Million | $-265.25K | 0.032x | +179.63% |
| 2001-07-31 | $-5.79 Million | $234.24K | -0.040x | -4328.85% |
| 2000-07-31 | $-2.72 Million | $-2.60K | 0.001x | +100.09% |
| 1999-07-31 | $-664.63K | $731.09K | -1.100x | -1962.50% |
| 1998-07-31 | $4.96 Million | $-264.60K | -0.053x | -168.00% |
| 1997-07-31 | $3.70 Million | $290.19K | 0.078x | -- |